Nausea and vomiting Survey during mild emetic antineoplastic drug combination(doublet study)

Nausea and vomiting Survey during mild emetic antineoplastic drug combination(doublet study) - Nausea and vomiting Survey during mild emetic antineoplastic drug combination(doublet study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018470

Enrollment

100

Registered

2015-09-01

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The case of the first dose in the regimen of chemotherapy planned 2.Cases of combination chemotherapy of antineoplastic agents between mild emetic risk (antiemetics proper use guidelines in 2014 [Version 1.2]) is planned

Exclusion criteria

Exclusion criteria: 1.Patients who experienced vomiting within chemotherapy before 24 hours 2.Day2 later also cases to use a mild emetic of anti-cancer drugs (except the oral anti-cancer agent) 3.Cases that enforce radiation therapy

Design outcomes

Primary

Measure	Time frame
Complete Response	—

Secondary

Measure	Time frame
Complete Control,Total Control	—

Countries

Japan

Contacts

Public ContactSakata Yukio

Hakodate Municipal hospital Pharmaceutical department

y-sakata@hospital.hakodate.hokkaido.jp0138-43-2000

Outcome results